<DOC>
	<DOCNO>NCT01269346</DOCNO>
	<brief_summary>This multicenter phase 2 study design evaluate safety efficacy eribulin mesylate combination trastuzumab first line treatment female subject locally recurrent metastatic human epidermal growth factor receptor ( HER2 ) positive breast cancer .</brief_summary>
	<brief_title>Eribulin With Trastuzumab First-line Therapy Locally Recurrent Metastatic HER2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Key Inclusion criterion : Age 18 year old Histologically cytologically proven adenocarcinoma breast Subjects locally recurrent metastatic disease least one measurable lesion HER2 positive determine score 3 immunohistochemistry ( IHC ) stain gene amplification fluorescence situ hybridization ( FISH ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) score 0 , 1 2 At least 12 month since prior neoadjuvant adjuvant chemotherapy At least 2 week since prior radiotherapy , endocrine therapy , trastuzumab , lapatinib , complete recovery effect intervention Adequate renal function Adequate bone marrow function Adequate liver function Adequate cardiac function Key Exclusion criterion : Prior chemotherapy , biologic therapy , investigational therapy locally recurrent metastatic HER2 breast cancer . Subjects prior malignancy carcinoma situ cervix , nonmelanoma skin cancer Prior exposure great 360 mg/m2 doxorubicin liposomal doxorubicin , great 120 mg/m2 mitoxantrone , great 90 mg/m2 idarubicin , great 720 mg/m2 epirubicin Inflammatory breast cancer Prior history hypertensive crisis hypertensive encephalopathy Clinically significant cardiovascular impairment Subjects know central nervous system ( CNS ) disease eligible , except subject treat brain metastasis . Subjects metastatic disease limit bone ineligible unless least one lytic lesion identifiable soft tissue component evaluate computed tomography ( CT ) magnetic resonance imaging ( MRI ) Pulmonary lymphangitic involvement result pulmonary dysfunction require use oxygen History bleed diasthesis Currently pregnant breastfeed . Subjects preexist Grade 3 4 neuropathy . Any peripheral neuropathy must recover Grade le equal 2 enrollment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Locally recurrent</keyword>
	<keyword>metastatic HER2Positive breast cancer</keyword>
</DOC>